More than half of patients with VHL-associated RCC in a phase 2 trial remained on belzutifan treatment, with no new safety signals. Belzutifan, a hypoxia-inducible factor-2α inhibitor, durably shrinks ...
The Von-Hippel Lindau (VHL) gene encodes for a tumor suppressor protein, pVHL, which is responsible for the regulation of a family cancer syndrome. Mutations in pVHL render the protein non-functional ...
Decision marks first approval for WELIREG in China and 17th approval of WELIREG for these patients globally In August 2021, WELIREG was approved in the U.S. for the treatment of adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback